Jesko Momotow
Koeln, NW, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Correlation between progression-free and overall survival in patients with Hodgkin lymphoma: a comprehensive analysis of individual patient data from randomized German Hodgkin Study Group (GHSG) trials.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: June 04, 2024
AFM13 in patients with relapsed or refractory classical Hodgkin lymphoma: final results of an open-label, randomized, multicenter phase II trial.
Journal: Leukemia & lymphoma
Published: July 18, 2022
AFM13 in patients with relapsed or refractory classical Hodgkin lymphoma: final results of an open-label, randomized, multicenter phase II trial.
Journal: Leukemia & lymphoma
Published: July 18, 2022
Outcomes of anti-programmed death 1 treatment for relapsed/refractory Hodgkin lymphoma: A German Hodgkin Study Group multicentre real-world analysis.
Journal: British journal of haematology
Published: February 02, 2022
Impact of the first COVID-19 lockdown in Germany on the rate of acute infections during intensive chemotherapy for Hodgkin lymphoma.
Journal: Infection
Published: November 23, 2021
Hodgkin Lymphoma-Review on Pathogenesis, Diagnosis, Current and Future Treatment Approaches for Adult Patients.
Journal: Journal of clinical medicine
Published: December 23, 2020
Nivolumab in Relapsed/Refractory Classical Hodgkin Lymphoma - Extended Follow-up of 30 Patients Treated Within the CheckMate 205 Trial in a Single-Center.
Journal: HemaSphere
Published: June 01, 2019
Leucocyte and eosinophil counts predict progression-free survival in relapsed or refractory classical Hodgkin Lymphoma patients treated with PD1 inhibition.
Journal: British journal of haematology
Published: April 26, 2017
Showing 1-9 of 9
Last Updated: 09/26/2026